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Aims Carotid intima–media thickness (CIMT) and plaque information can improve coronary heart disease (CHD) risk pre-
diction when added to traditional risk factors (TRF). However, obtaining adequate images of all carotid artery seg-
ments (A-CIMT) may be difficult. Of A-CIMT, the common carotid artery intima–media thickness (CCA-IMT) is
relatively more reliable and easier to measure. We evaluated whether CCA-IMT is comparable to A-CIMT when




Ten-year CHD risk prediction models using TRF alone, TRF + A-CIMT + plaque, and TRF + CCA-IMT + plaque
were developed for the overall cohort, men, and women. The area under the receiver operator characteristic
curve (AUC), per cent individuals reclassified, net reclassification index (NRI), and model calibration by the Grøn-
nesby–Borgan test were estimated. There were 1722 incident CHD events in 12 576 individuals over a mean
follow-up of 15.2 years. The AUC for TRF only, TRF + A-CIMT + plaque, and TRF + CCA-IMT + plaque models
were 0.741, 0.754, and 0.753, respectively. Although there was some discordance when the CCA-IMT + plaque-
and A-CIMT + plaque-based risk estimation was compared, the NRI and clinical NRI (NRI in the intermediate-risk
group) when comparing the CIMT models with TRF-only model, per cent reclassified, and test for model calibration
were not significantly different.
Conclusion Coronary heart disease risk prediction can be improved by adding A-CIMT + plaque or CCA-IMT + plaque infor-
mation to TRF. Therefore, evaluating the carotid artery for plaque presence and measuring CCA-IMT, which is
easier and more reliable than measuring A-CIMT, provide a good alternative to measuring A-CIMT for CHD risk
prediction.
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Introduction
Carotid intima–media thickness (CIMT) is a well-established sur-
rogate of atherosclerosis and has been associated with both preva-
lent and incident cardiovascular disease (CVD).1,2 Furthermore,
CIMT has also been used as a surrogate endpoint to monitor
the efficacy of therapy against atherosclerosis in clinical trials.3 –5
Among the limitations frequently cited in measuring of CIMT is
the difficulty to adequately image all carotid artery segments,
especially the internal carotid artery (ICA). In the Atherosclerosis
Risk in Communities (ARIC) study, 51.4% of the ICA segments
when compared with 9% of common carotid artery (CCA) seg-
ments could not be imaged.6,7 Similarly, in the Rotterdam study,
CIMT measurements were possible in 96% of the CCA segments
when compared with 31% of the ICA segments.8 Even though one
would now expect that technically adequate images of the ICA and
CCA can be more frequently obtained with the advances in ultra-
sound technology, the ICA still remains the more difficult of the
carotid artery segments to image; and therefore, it is less
reliable.9,10 There has been no carotid artery segment (i.e. com-
parison among the various segments) that has clearly demon-
strated a more significant association with CVD; some reports
suggest that the CCA may have marginally higher adjusted relative
risk (RR) for stroke prediction, whereas the ICA may have margin-
ally higher RR for coronary heart disease (CHD) risk prediction.2
Finally, measuring all carotid segments significantly increases the
time required to complete a study. Based on all of the above, the
American Society of Echocardiography and Society of Vascular
Medicine and Biology concluded, in a report on the use of vascular
ultrasound in cardiovascular risk stratification, that ‘there does not
appear to be compelling evidence to suggest that combined
measurements or measurement of a specific segment is clearly
superior’ and recommended the use of the CCA segment for
improved reproducibility.9
We have recently shown that adding the mean CIMT of all
carotid artery segments (common, bulb, and internal carotid
arteries) (A-CIMT) and plaque information to traditional risk
factors (TRF) improves CHD risk prediction in the ARIC study.11
We tested, in the ARIC study, whether adding CCA-IMT and
plaque is as good as adding A-CIMT and plaque to TRF in improv-
ing CHD risk prediction. If CCA-IMT is comparable to A-CIMT,
it will have significant clinical and possible research implications




The ARIC study is a population-based study of CVD incidence which
enrolled 15 792 individuals in four communities in the USA between
1987 and 1989. Study details have been published previously.12 Data
collected during the baseline ARIC visit included information about
the TRF for CVD and carotid artery ultrasound. For this analysis, we
excluded individuals with prevalent CHD (n ¼ 763), missing CIMT
or CCA-IMT data (n ¼ 1478), missing CHD prevalence data
(n ¼ 339), missing TRF data (n ¼ 533), races other than ‘black’ or
‘white’ (n ¼ 48), and black participants from the Minnesota or
Washington field centre (n ¼ 55). This provided us with a study
sample of 12 576 individuals.
Ultrasound measurements
The ultrasound protocol to measure CIMT in the ARIC study has been
described previously.13 –16 Briefly, measurements were made in a 1 cm
segment in the distal CCA (1 cm proximal to dilation of the carotid
bulb), 1 cm of the carotid artery bifurcation (1 cm proximal to the
flow divider), and 1 cm in the proximal ICA (1 cm section of the
ICA immediately distal to the flow divider) of both right and left
sides using a Biosound 2000IISA system (8 MHz transducer, axial res-
olution 0.10 mm, and an effective lateral resolution in the focal plane
slightly better than 1.0 mm). Eleven far-wall mean and maximum CIMT
measures were obtained at 1 mm increments. In addition, information
about the presence or absence of plaque was also recorded. The pres-
ence of plaque was judged by trained readers using the presence or
absence of two of the following three criteria: abnormal wall thickness
(defined as CIMT .1.5 mm), abnormal shape (protrusion into the
lumen and loss of alignment with adjacent arterial wall boundary),
and abnormal wall texture (brighter echoes than adjacent bound-
aries).14,17 For the purpose of this analysis, both the mean far-wall
IMT of the right and left carotid arteries and information about the
presence or absence of plaque in each subject were used. The repro-
ducibility of CIMT and plaque measurements has been published pre-
viously.14,15,18 Overall, of all the segments, the CCA measurements
had the best coefficient of variation, although not the best reliability
coefficient. However, it must be noted that 57% of ICA measure-
ments had to be imputed due to poor image quality, whereas only
9% of the CCA measurements had to be imputed. We excluded
those with missing CCA-IMT for our analysis, whereas imputed
values (single imputation method) were used for missing ICA and
bulb measurements. In secondary analyses, we used only the non-
imputed (i.e. available measured values) IMT measurements for each
subject. However, since IMT values at the bulb, CCA, and ICA vary,
we adjusted the measurements at each segment to have a weighted
mean equal to the unadjusted population mean over all sites.
Incident coronary heart disease events
Follow-up included for this analysis was until December 2005. Incident
CHD events included definite or probable myocardial infarction (MI),
silent MI between examinations indicated by electrocardiograms, defi-
nite CHD death, or coronary revascularization. In additional analyses,
we considered only ‘hard’ CHD endpoints which included MI and defi-
nite CHD death only. Methods used to ascertain these events in the
ARIC study and the quality control measures used have been published
previously.19
Statistical analysis
We used SAS version 9.1 for all analyses. A P-value of ,0.05 was con-
sidered to be statistically significant, and we used two-tailed tests to
assess the P-values. The following models were considered: (i)
TRF-only; (ii) TRF + A-CIMT + plaque; and (iii) TRF + CCA-IMT +
plaque. The evaluated TRF models included the ARIC coronary risk
score (ACRS) 20 and the Framingham risk score (FRS). We did this
as the ACRS represents the best model to predict CHD risk in the
ARIC study, whereas the FRS model is the model most used clinically.
In secondary analysis, we also estimated SCORE21 and the effect of
adding the two IMT models to it. The TRF that constitute the
ACRS, FRS, and SCORE are presented in Supplementary material
online, Table S1. ACRS includes age and its quadratic form (age2),
sex, systolic blood pressure, antihypertensive medication use, total
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cholesterol, HDL cholesterol, diabetes, and smoking status. The
analyses were performed for the overall cohort and then by gender.
Carotid intima–media thickness was classified into sex-specific percen-
tile categories of ,25th percentile, 25–75th percentile, and .75th
percentile. For A-CIMT, all the segments were used to derive the
percentile cut-points, whereas for CCA-IMT, only the CCA-IMT
segment was used. The concordance and discordance between
A-CIMT and CCA-IMT (i.e. percentile categories) and the observed
and predicted risk in these various categories were described.
The area under the receiver operator characteristic curve (AUC)
for 10-year risk was then calculated accounting for censoring,22 and
bootstrapping was performed to furnish 95% confidence intervals
for the differences in the adjusted AUC and to correct for over
optimism.23–25
The study population was classified into various 10-year CHD risk
groups (0–5% or low risk, 5–10% or low–intermediate risk,
10–20% or intermediate–high risk, and .20% or high risk) for the
different models (except SCORE) using Cox’s proportional hazards
models. The number of individuals reclassified (i.e. the number that
changed groups when one model was compared with the other)
was then described. The net reclassification index (NRI), clinical NRI,
and the integrated discrimination index (IDI)26 were described using
a method accounting for censoring.27 The 95% confidence intervals
for the differences between the models were again furnished by
bootstrapping.
Finally, the calibration of the various models (comparing the
expected and observed events based on the Kaplan–Meier 10-year
estimates) was tested using the Grønnesby–Borgan goodness-of-fit
statistic.28 Smaller values of the test statistic (i.e. non-significant
P-values) suggested good model fit (i.e. better calibration) when the
observed and expected events are compared.
Results
Over a mean follow-up of 15.1 years (median follow-up ¼ 16.8
years, inter-quartile range ¼ 2.5 years), there were 1722 incident
CHD events (632 in women and 1090 in men) in the 12 576
(7121 women and 5455 men) individuals included in this analysis.
Of the 1722 incident events, there were 153 fatal CHD events,
820 MIs, 91 additional ECG-confirmed MIs, and 658 revasculariza-
tion procedures. The baseline characteristics of the study cohort
are listed in Table 1. The 25th and 75th percentile for the mean
of all CIMT (A-CIMT) segments was 0.61 and 0.78 mm, respect-
ively, for the entire cohort, whereas it was 0.65 and 0.84 mm,
respectively, for men and 0.58 and 0.74 mm, respectively, for
women. On the other hand, as expected, the 25th and 75th per-
centiles for CCA-IMT were lower: 0.53 and 0.70 mm, 0.55 and
0.74 mm, and 0.51 and 0.67 mm, respectively, for the overall
group, men, and women.
When individuals were classified into ,25th, 25–75th, and
.75th percentile based on their sex-specific A-CIMT and
CCA-IMT values, some discordance between the classification
was observed (Table 2). Overall, for each group, approximately
two-thirds were concordant (i.e. belonged to the same percentile
group) and one-third was discordant (i.e. belonged to a different
percentile group). Although the majority among the discordant
individuals were classified to the immediately higher or lower
group (e.g. moving from ,25th percentile when CCA-IMT alone
was used to 25–75th percentile when A-CIMT was used), a
small number of individuals were reclassified from one extreme
to the other (e.g. reclassified from ,25th percentile by one
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Table 1 Baseline characteristics of the study population [means (SD) or prevalence %] after exclusions: ARIC study,
1987–89
Variable Men (n 5 5455) Women (n 5 7121) Entire population (n 5 12 576)
Age (years) 54.4 (5.8) 53.8 (5.7) 54.0 (5.8)
Body mass index (kg/m2) 27.2 (4.0) 27.3 (5.7) 27.3 (5.1)
Systolic blood pressure (mmHg) 122.2 (17.7) 119.6 (19.2) 120.7 (18.6)
Diastolic blood pressure (mmHg) 75.5 (11.2) 71.9 (10.9) 73.5 (11.2)
Total cholesterol (mg/dL) 210.1 (39.4) 216.9 (42.1) 214.0 (41.1)
Triglycerides (mg/dL) 129.6 (66.7) 116.1 (59.8) 122.0 (63.2)
High-density lipoprotein cholesterol (mg/dL) 45.4 (13.9) 58.4 (17.2) 52.7 (17.1)
Low-density lipoprotein cholesterol (mg/dL) 138.8 (37.1) 135.3 (40.3) 136.8 (39.0)
A-CIMT 25th percentile (mm) 0.65 0.58 0.61
A-CIMT 75th percentile (mm) 0.84 0.74 0.78
CCA-IMT 25th percentile (mm) 0.55 0.51 0.53
CCA-IMT 75th percentile (mm) 0.74 0.67 0.70
Whites (%) 77.2 72.5 74.5
Diabetes (%) 10.1 9.8 9.9
Eight-hour (or more) fasting glucose (mg/dL) 106.2 (28.0) 103.8 (32.2) 104.9 (30.5)
Current tobacco use (%) 27.8 25.2 26.3
Former tobacco use (%) 43.0 22.6 31.5
Cholesterol-lowering medication use (%) 2.1 2.4 2.3
Statin use (%) 0.30 0.51 0.42
Aspirin use (%) 40.9 49.4 45.7
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CIMT classification to .75th percentile by the other CIMT classi-
fication and vice versa). The 10-year observed risk based on the
concordant and discordant CIMT categories is presented in
Supplementary material online, Table S2. Overall, in general, the
observed risk approximated that predicted by the higher of the
discordant IMT categories.
Discrimination and reclassification
There were significant increases in the AUCs adjusted for
optimism when A-CIMT+ or CCA-IMT + plaque + TRF models
were compared with the TRF-only model (Table 3). However,
there was no difference when the CCA-IMT + plaque + TRF
model was compared with the A-CIMT + plaque + TRF model.
In the overall group, adding CCA-IMT + plaque and A-CIMT +
plaque to the TRF (ACRS-based) model resulted in reclassification
of 2826/12 576 (22.5%) individuals and 2911/12 576 (23.1%) of the
individuals, respectively (see Supplementary material online, Tables
S3 and S4). When the CCA-IMT + plaque + TRF model was com-
pared with the A-CIMT + plaque + TRF model, 1033/12 576 or
8.2% of the individuals were reclassified or discordant (Table 4;
see Supplementary material online, Tables S5A and B) which
suggested that the use of CCA-IMT instead of A-CIMT (or vice
versa) may result in 8% of the individuals being classified into
an alternate risk category. However, all individuals were either
reclassified up or down by only one risk category (i.e. no individ-
uals were reclassified from low to high risk or vice versa). If FRS
was used as the TRF model, 34.4 and 33.7% of the individuals
were reclassified when A-CIMT + plaque and CCA-IMT +
plaque were added to the FRS-based TRF model, respectively,
whereas 1326/12 576 or 10.5% of the individuals were reclassified
when the CCA-IMT + plaque + TRF model was compared with
the A-CIMT + plaque + TRF model (both FRS-based). Again, all
individuals were either reclassified up or down by only one
risk category).
The NRI and clinical NRI for both A-CIMT + plaque and
CCA-IMT + plaque models were significant when compared
with either of the TRF-only models (ACRS- or FRS-based) in the
overall group, men, and women (Table 5) except when adding
A-CIMT + plaque to the ACRS or FRS in women and adding
CCA-IMT + plaque to the FRS in women when the NRI was not
significant. However, when models with CCA-IMT were compared
with models with A-CIMT, there was no difference in the NRI or
clinical NRI, suggesting that both models were comparable.
When the IDI was evaluated in the overall population, the IDI
was 0.010 when CCA-IMT + plaque + TRF was compared with
the TRF-only (ACRS-based) model, whereas the IDI was 0.011
for all other comparisons: A-CIMT + plaque + TRF (ACRS) vs.
TRF-only (ACRS), A-CIMT + plaque + TRF (FRS) vs. TRF-only
(FRS) and CCA-IMT + plaque + TRF (FRS) vs. TRF-only (FRS).
In secondary analyses, when we disregarded imputed IMT values
and only used normalized observed IMT values, no major differ-
ences in risk prediction statistical parameters were noted
between A-CIMT + plaque + TRF and CCA-IMT + plaque +
TRF (ACRS- or FRS-based) models (see Supplementary material
online, Tables S6 and S7).
Model calibration
Finally, when the goodness-of-fit statistic was calculated, CCA-IMT
and A-CIMT performed similarly by improving model fit when
added to TRF, compared with TRF-only (FRS- or ACRS-based)
models (see Supplementary material online, Table S8). The only
model that was not improved (i.e. x2 statistic increased) was
when CCA-IMT was added to ACRS in women; however, even
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Table 3 Adjusted area under the curves for the various models in the overall population, men, and women and the
differences in area under the curves when compared with other models: the ARIC study
Model Overall Men Women
ACRS-only 0.741 0.672 0.760
ACRS + A-CIMT + plaque; comparison with ACRS alone,
difference (95% CI)
0.754 0.692 0.771
0.0129 (0.0086, 0.0166) 0.0200 (0.0115, 0.0270) 0.0109 (0.0040, 0.0157)
ACRS + CCA-IMT + plaque; comparison with ACRS alone,
difference (95% CI)
0.753 0.690 0.771
0.0121 (0.0078, 0.0158) 0.0179 (0.0090, 0.0242) 0.0109 (0.0040, 0.0158)
ACRS + A-CIMT + plaque vs. ACRS + CCA-IMT + plaque,
difference (95% CI)
20.0008 (20028, 0.0013) 20.0021 (20068, 0.0025) 0.0000 (20.0028, 0.0027)
Mean AUC differences were calculated as model with CIMT – ACRS-only model. For comparison of the CCA-IMT model with A-CIMT model, the mean difference was
calculated as CCA-IMT – A-CIMT model.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Concordance and discordance of intima–
media thickness distribution by percentiles when
common carotid artery intima–media thickness is








,25th percentile 2053 1093 29 3175
Row % 64.66 34.43 0.91
25–75th percentile 951 4238 1048 6237
Row % 15.25 67.95 16.80
.75th percentile 139 959 2066 3164
Row % 4.39 30.31 65.30
Total 3143 6290 3143 12 576
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in this case, the model fit remained ‘good’. Therefore, overall, the
addition of CCA-IMT was comparable if not better than A-CIMT
with respect to model fit when added to TRF.
Hard coronary heart disease endpoints
When we examined hard CHD endpoints (e.g. MI or CHD death),
the results were similar; both CCA-IMT and A-CIMT improved risk
prediction and were comparable to each other (see Supplemen-
tary material online, Table S9A and B).
Cardiovascular mortality
When we examined adding CCA-IMT + plaque or A-CIMT +
plaque to SCORE in the prediction of both fatal CHD and
non-CVD death in secondary analysis, there was once again no
noted significant differences between the use of A-CIMT +
plaque and CCA-IMT + plaque. Overall, 87% of the men and
98% of the women were low risk (,2% 10-year risk). When
either A-CIMT + plaque or CCA-IMT + plaque was added to
SCORE and compared with SCORE alone, only 1% of the
women were reclassified, whereas 20% of the men were reclas-
sified. In men, the unadjusted AUC for SCORE-only, A-CIMT +
plaque + SCORE, and CCA-IMT + plaque + SCORE were 0.591,
0.706, and 0.708, respectively, whereas in women, they were
0.619, 0.690, and 0.689, respectively. The NRI, clinical NRI, IDI,
and per cent reclassified for men are provided in Supplementary
material online, Table S10. For the women, given 1% reclassifica-
tion, we do not believe that the NRI and clinical NRI provide much
information and, therefore, have not included them.
Discussion
Carotid intima–media thickness has consistently been shown to be
associated with cardiovascular risk factors and incident and preva-
lent CHD.9,29 The test is safe but the ability to obtain accurate and
repeatable measurements has been a concern. Of all the segments
of the carotid artery which have been used in CIMT measurement,
the CCA is the easiest to image and has the highest reproducibility;
and therefore, it has been recommended as the segment to utilize
for CIMT measurements.9
Some investigations have compared the different carotid artery
segments with respect to their association with CVD. In the Car-
diovascular Health Study,2 the combination of CCA-IMT and
ICA-IMT had numerically higher RR for incident MI or stroke
when compared with either CCA-IMT or ICA-IMT alone (RR:
1.36 vs. 1.27 and 1.30, respectively). When ICA-CIMT was com-
pared with CCA-IMT, ICA-IMT had higher RR for incident CHD
(1.34 vs. 1.24), whereas CCA-IMT had a higher RR for incident
stroke (1.38 vs. 1.25). Overall, there has not been a clearly
superior carotid artery segment associated with CVD.
Recently, we have shown that CIMT (based on the measure-
ment of all carotid segments) and information about the presence
or absence of plaque have the ability to significantly improve CHD
risk prediction.11 Few other efforts have examined the utility of
CIMT in risk assessment but each with limitations.30 Most recently,
Lorenz et al.31 examined the Carotid Atherosclerosis Progression
Study (CAPS) and reported that CIMT did not improve CHD risk
prediction and that there were no differences when individual
carotid artery segments were examined for their risk predictive
abilities. However, this study was limited as there were no
follow-up visits to assess clinical outcomes, and clinical outcomes
were ascertained primarily by ICD codes. In fact, even in the
group with the highest predicted risk determined by TRF (i.e.
.20% predicted 10-year risk), the Kaplan–Meier estimated
observed risk was only 3.03%. Furthermore, they did not report
whether CCA-IMT used alone was as good as A-CIMT in CHD
risk prediction. Hence, we examined in the ARIC study whether
CCA-IMT + plaque can improve CHD risk prediction similar to
that obtained when A-CIMT was used and found that both
measurements (i.e. CCA-IMT-only or A-CIMT) gave similar
results for the most part. However, interestingly, approximately
one-third of the individuals were discordant when CCA-IMT and
A-CIMT categories were compared [i.e. individuals classified as
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Table 4 Reclassification when A-CIMT 1 plaque 1 TRF (ACRS-based) is compared with CCA-IMT 1 plaque 1 TRF
(ACRS-based) for the entire group (those with and without events) with 10-year Kaplan–Meier risk estimates
CHD risk by TRF 1
A-CIMT 1 plaque










≤5%, low risk (row %) 5967 (96.3) 229 (3.7) 0 0 6196
KM 10-year risk, % 1.9 6.2 — — 2.1
5–10%, low–intermediate risk (row %) 229 (6.9) 2897 (87.1) 201 (6.0) 0 3327
KM 10-year risk, % 5.4 7.3 9.2 — 7.3
10–20%, intermediate-high risk (row %) 0 191 (8.7) 1919 (87.4) 85 (3.9) 2195
KM 10-year risk, % — 13.8 15.1 22.0 15.0
.20%, high risk (row %) 0 0 98 (11.4) 760 (88.6) 858
KM 10-year risk, % — — 19.1 28.7 27.7
All (row %) 6196 (49.3) 3317 (26.4) 2218 (17.6) 845 (6.7) 12 576 (100)
KM 10-year risk, % 2.1 7.6 14.7 27.4 7.3
KM, Kaplan–Meier.
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,25th , 25–75th, and .75th percentile with one CIMT schema
(A-CIMT or CCA-IMT) were in another category when the
other CIMT schema was used], whereas 8–10% of the individ-
uals were discordant when risk categories after risk estimation
were compared using CIMT (CCA-IMT vs. A-CIMT) + plaque +
TRF. This suggests that the majority of the discordance in the
CIMT categories did not affect risk estimation (approximately
one-third discordant by CIMT categories compared with 1/10th
by risk stratification categories) which is likely because most dis-
cordance reclassified individuals to the CIMT category that was
immediately above or below, thereby resulting only in limited
changes in the contribution of CIMT in risk estimation, and
because the presence/absence of plaque was factored in estimating
risk in both CIMT (CCA-IMT and A-CIMT) risk prediction
schemes. However, although 8–10% of the individuals were
classified into different risk categories depending on whether
CCA-IMT or A-CIMT was added to the risk prediction scheme,
there were no major statistical differences when these two
CIMT strategies were compared, suggesting that correct and incor-
rect reclassifications by these two strategies (CCA-IMT vs.
A-CIMT) ‘evened’ out. Furthermore, when observed risk was eval-
uated in the discordant IMT categories (see Supplementary
material online, Table S2), in general, the risk remained in step
with the higher of the two discordant CIMT strategies (i.e.
CCA-IMT vs. A-CIMT). Overall, based on our results, it is
evident that adding A-CIMT + plaque or CCA-IMT + plaque to
TRF can both improve CHD risk prediction, and neither strategy
is superior to the other.
Our analysis has clinical and potential research significance. In a
clinical setting, it would not be possible for the practitioner to
impute values for missing CIMT segments as in our analyses.
Even though current-day technological advancements will result
in significantly lesser poor-quality/missing images, the CCA still
remains the most reliable and easiest segment to image. Further-
more, optimal image acquisition is critical in the measurement of
CIMT as small changes in values can be clinically important and
meaningful. For example, the difference in the mean CCA-IMT
between the 25th and 75th percentile for a 45-year-old man is
0.16 mm in the ARIC study. Changes in the angle of image acqui-
sition can clearly affect IMT measurements. The ICA may branch
off at an angle, and the bifurcation of the carotid artery may
occur high in the neck, all of which can make ICA imaging a chal-
lenge even in this day and age. Therefore, one could recommend
that clinicians who use CIMT in their practice for CHD risk esti-
mation use a protocol that measures CCA-IMT and a sweep of
the carotid arteries for the presence/absence of plaque given
that: (i) CCA-IMT is the CIMT segment least likely to be missing,
(ii) CCA-IMT is the most reproducible and easiest to image the
various CIMT measurements, and (iii) our analysis now shows
that a sweep of the entire carotid artery for the presence/
absence of atherosclerotic plaque in concert with measurement
of CCA-IMT or A-CIMT are comparable.
Similarly, in atherosclerosis research, CIMT is a commonly used
and accepted surrogate endpoint in clinical trials.32,33 However,
most often, IMT of all carotid segments is used as the primary end-
point. Whether the use of CCA-IMT alone will perform as well as
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explored. If CCA-IMT is comparable to the use of all IMT seg-
ments, this will again improve repeatability of the study and will
allow for easier and more efficient protocols. However, other
factors, including that atherosclerosis tends to occur more fre-
quently in the bulb and internal carotid arteries, will need to be
considered.
Limitations
We used data only from the baseline (1987–89) ARIC visit (CIMT
and TRF) to perform our current analysis. Whether using infor-
mation (including TRF and CIMT) from subsequent ARIC visits
could change the results is not clear. Furthermore, we have not
accounted for changes in medications (e.g. new medications
being prescribed) over the course of the study period. Subsequent
use of medications that decrease CHD events (such as statins)
could alter the observed outcomes and therefore have impacted
on the risk predictive abilities of CIMT; however, this would
have been similar when A-CIMT was compared with CCA-IMT.
Our data used CIMT measurements from only one time point.
Given that data have suggested that CIMT progression in the
various carotid segments may vary, it is unclear whether similar
results will be found if one factored in the change in CCA-IMT
vs. A-CIMT over time. We used imputed values for missing
CIMT segments using a technique that has been validated7;
however, it is not clear whether there would have been a differ-
ence had actual measurements been available. Finally, it is not
clear whether the use of more contemporary ultrasound technol-
ogy with lesser variability and improved resolution would have led
to different results when CCA-IMT and A-CIMT are compared in
CHD risk prediction.
Conclusions
A strategy of measuring CCA-IMT alone in concert with plaque
information improves CHD risk prediction and is comparable to
using all CIMT segments in the ARIC study. Whether a strategy
of making therapeutic decisions using CIMT in addition to TRF
when compared with using TRF alone in CHD risk prediction
will prevent CHD events will need to be studied in clinical trials.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Interventricular septum rupture after transcatheter aortic valve
implantation
Marina I. Revilla Martı́nez*, Hipólito Gutiérrez Garcı́a , and José Alberto San Román Calvar
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A 76-year-old woman with hypertension,
severe chronic obstructive pulmonary
disease, and severe aortic valve stenosis
with preserved left-ventricular ejection frac-
tion was referred by dyspnoea. High surgical
risk was calculated (EuroSCORE: 17%);
therefore, transcatheter aortic valve implan-
tation (TAVI) was planned.
Aortic valve was dilated with a 22 mm
Nucleusw balloon and a 26 mm CoreValvew
prosthesis was implanted. Aortography
revealed residual severe aortic regurgitation
owing to incomplete valve expansion. There-
fore, a 25 mm Nucleusw balloon dilatation
was performed. A new aortogram showed
grade 1 aortic regurgitation and a tiny
contrast pass from left to right ventricle
(Figure A, arrow).
The patient developed symptoms of heart
failure. Transthoracic echocardiography
showed interventricular septum rupture (ISR) at the level of membranous septum, in apical (Figure C) and short-axis views
(Figure D). Defect size was 6 mm (Figure E). Interventricular septum rupture surgical repair was refused because of high risk. The
patient improved clinically and was discharged asymptomatic on Day 12.
Interventricular septum rupture contributing factors after TAVI are unknown. In our series of 50 patients, 6 required postdilatation
with balloon and only one ISR occurred. Computed tomography in our patient showed calcification extending from aortic valve to the
beginning of the membranous septum. Membranous septum size was 8.7 mm (Figure B, arrows), which is longer than the median length
in our patients (3 mm). It is too early to determine the predisposing factors for ISR post-TAVI; however, a severely calcified membra-
nous septum longer than usual and overdilatation of the prosthesis could contribute to this complication.
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